Xencor (XNCR) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings or view top-rated stocks.

11 brokers have issued 1 year price targets for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's share price to reach $45.33 in the next year. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts.

Xencor's stock was trading at $26.04 at the beginning of the year. Since then, XNCR shares have increased by 6.3% and is now trading at $27.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our XNCR earnings forecast.

Xencor, Inc. (NASDAQ:XNCR) posted its earnings results on Monday, May, 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.27. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analysts' expectations of $26.89 million. Xencor had a negative net margin of 142.32% and a negative trailing twelve-month return on equity of 19.41%. The firm's revenue was down 77.9% compared to the same quarter last year. During the same period last year, the business posted $0.39 EPS.

ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Raymond James SB-1 Equity ETF (RYJ) and Principal Healthcare Innovators ETF (BTEC).

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.43%), FMR LLC (6.22%), Price T Rowe Associates Inc. MD (5.45%), State Street Corp (5.43%), Dimensional Fund Advisors LP (2.56%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch.
View institutional ownership trends.

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XNCR stock can currently be purchased for approximately $27.69.

Xencor (NASDAQ:XNCR) has a market capitalization of $1.67 billion and generates $98.05 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

The company employs 254 workers across the globe.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.